Cytometry of antitumor drug-intracellular target interactions

Methods in Cell Biology

Volumn 64, Issue 64, 2001, Pages 173-191

  Smith, Paul J ^a   Wiltshire, Marie ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; DNA; DNA FRAGMENT; DNA TOPOISOMERASE; ETOPOSIDE; FLUORESCENT DYE; HOE 33342; LIGAND;

ARTICLE; CELL CULTURE; CELL CYCLE; CONFOCAL MICROSCOPY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; METABOLISM; METHODOLOGY;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CELL CYCLE; DNA; DNA FRAGMENTATION; DNA TOPOISOMERASES, TYPE I; DRUG DELIVERY SYSTEMS; ETOPOSIDE; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; LIGANDS; MICROSCOPY, CONFOCAL; TUMOR CELLS, CULTURED;

EID: 0035233886     PISSN: 0091679X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0091-679x(01)64013-5     Document Type: Article

References (35)

1. Anderson, R. D., and Berger, N. A. (1994). Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat. Res. 309, 109-142.
2. Bell, D. H. (1988). Characterization of the fluorescence of the antitumour agent, mitoxantrone. Biochim. Biophys. Acta 949, 132-137.
3. Bowden, G. T., Roberts, R., Alberts, D. S., Peng, Y.-M., and Garcia, D. (1985). Comparative molecular pharmacology in leukaemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene. Cancer Res. 45, 4915-4920.
4. Broggini, M., Erba, E., Ponti, M., Geroni, C., Spreafico, F., and D'Incalci, M. (1991). Selective DNA interaction of the novel distamycin derivative FCE 24517. Cancer Res. 51, 199-209.
5. Chabner, B. A. (1992). Mitotic inhibitors. Cancer Chemother. Biol. Response Modif. 13, 69-74.
6. Chen, A. Y., and Liu, L. F. (1994). DNA topoisomerases: Essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 34, 191-218.
7. Cummings, J., and Smyth, J. F. (1993). DNA topoisomerase-I and topoisomerase-II as targets for rational design of new anticancer drugs. Ann. Oncol. 4, 533-543.
8. Eng, W.-K., Faucette, L., Johnson, R. K., and Sternglanz, R. (1988). Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol. 34, 755-760.
9. Fox, M. E., and Smith P. J. (1995). Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells. Cancer Chemother. Pharmacol. 35, 403-410.
10. Gervasoni, J. E., Jr., Fields, S. Z., Krishna, S., Baker, M. A., Rosado, M., Thurasamy, K., Hindenburg, A. A., and Taub R. N. (1991). Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res. 51, 4955-4963.
11. Hsiang, Y.-H., Hertzberg, R., Hecht, S., and Liu, L. F. (1985). Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase Int. J. Biol. Chem. 260, 14873-14878.
12. Kluin-Nelemans, H. C., Limpens, J., Meerabux, J., Beverstock, G. C., Jansen, J. H., de Jong, D., and Kluin, P. M. (1991). A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14,18)(q32,q21). Leukemia 5, 221-224.
13. Kolber, M. A., Broschat, K. O., and Landa-Gonzalez, B. (1990). Cytochalasin B induces cellular DNA fragmentation. FASEB J. 4, 3021-3027.
14. Krishan, A., and Ganapathi, R. (1980). Laser flow studies on the intracellular fluorescence of anthracyclines. Cancer Res. 40, 3895-3900.
15. Liu, L. F. (1989). DNA topoisomerase poisons as anti-tumour drugs. Annu. Rev. Biochem. 58, 351-375.
16. Lown, J. W., Morgan, A. R., Yen, S.-F., Wang, Y. H., and Wilson, W. D. (1985). Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. Biochemistry 24, 4028-4035.
17. Mahajan, N. P., Linder, K., Berry, G., Gordon, G. W., Heim, R., and Herman, B. (1998). Bcl-2 and Bax interactions in mitochondria probed with green fluorescent protein and fluorescence resonance energy transfer. Nature Biotechnol. 16, 547-52.
18. Mir, L. M., Tounekti, O., and Orlowski, S. (1996). Bleomycin: Revival of an old drug. General Pharmacol. 27, 745-748.
19. Roberts, R. A., Cress, A. E., and Dalton, W. S. (1989). Persistent intracellular binding of mitoxantrone in a human colon carcinoma cell line. Biochem. Pharmacol. 38, 4283-4290.
20. Robinson, M. J., and Osheroff, N. (1990). Stabilization of the topoisomerase II DNA cleavage complex by antineoplastic drugs - inhibition of enzyme-mediated DNA religation by 4′-(9-acridinyl-amino)-methane-sulfon-m-anisidide. Biochemistry 29, 2511-2515.
21. Rowe, T. C., Chen, G. L., Hsiang, Y.-H., and Liu, L. F. (1986). DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res. 46, 2021-2026.
22. Schilsky, R. L. (1996). Methotrexate: An effective agent for treating cancer and building careers. The polyglutamate era. Stem Cells 14, 29-32.
23. Schneider, E., Hsiang, Y. H., and Liu, L. F. (1990). DNA topoisomerases as anticancer drug targets. Adv. Pharmacol. 21, 149-183.
24. Schwartz, H. S. (1973). A fluorometric assay for daunomycin and adriamycin in animal tissues. Biochem. Med. J. 7, 396-404.
25. Smith, P. J. (1990). DNA topoisomerase dysfunction: A new goal for antitumor chemotherapy. BioEssays 12, 167-172.
26. Smith, P. J., and Makinson T. A. (1989). Cellular consequences of overproduction of DNA topoisomerase II in an ataxia-telangiectasia cell line. Cancer Res. 49, 1118-1124.
27. Smith, P. J., and Soues, S. (1994). Multilevel therapeutic targeting by topoisomerase inhibitors. Br. J. Cancer 70, 47-51.
28. Smith, P. J., Morgan, S. A., Fox, M. E., and Watson, J. V. (1990). Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem. Pharmacol. 40, 2069-2078.
29. Smith, P. J., Morgan, S. A., and Watson, J. V. (1991). Detection of multidrug resistance and quantification of responses of human tumour cells to cytotoxic agents using flow cytometric spectral shift analysis of Hoechst 33342-DNA fluorescence. Cancer Chemother Pharmacol. 27, 445-450.
30. Smith, P. J., Sykes, H. R., Fox, M. E., and Furlong, I. J. (1992). Subcellular distribution of the anticancer drug mitoxantrone in human and drug-resistant murine cells analyzed by flow cytometry and confocal microscopy and its relationship to the induction of DNA damage. Cancer Res. 52, 1-9.
31. Smith, P. J., Rackstraw, C., and Cotter, F. (1994a). DNA fragmentation as a consequence of cell cycle traverse in doxorubicin and idarubicin treated human lymphoma cells. Ann. Haematol. 69, 7-11.
32. Smith, P. J., Soues, S., Gottlieb, T., Falk, S. J., Watson, J. V., Osborne, R. J., and Bleehen, N. M. (1994b). Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small cell lung cancer cells. Br. J. Cancer 70, 914-921.
33. Smith, P. J., Desnoyers, R., Patterson, L. H., and Watson, J. V. (1997). Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647 nm krypton laser excitation. Cytometry 27, 43-53.
34. Yanowich, S., and Taub, R. N. (1983). Differences in daunomycin retention in sensitive and resistant P388 leukemic cells as determined by digitized video fluorescence microscopy. Cancer Res. 41, 4167-4171.
35. Zhang, H., D'Arpa, P., and Liu, L. F. (1990). A model for tumour cell killing by topoisomerase poisons. Cancer Cells 2, 23-27.